Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study

PurposeTo investigate the efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC).MethodsA total of 100 patients with advanced squamous NSCLC undergoing initial treatment at our hospital between January 2021 and early January 2023 were enrolled. Patients were categorized into an experimental group (n=50) and a control group (n=50). The control group received tislelizumab plus chemotherapy, while the experimental group received deep hyperthermia combined with tislelizumab and chemotherapy. The main objective was objective response rate (ORR). Secondary endpoints encompassed overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and safety.ResultsORR in the experimental group was 66.0% (33/50), with a DCR of 86.0% (43/50). The ORR and DCR in the control group were 46.0% (23/50) and 84.0% (42/50), respectively. ORR in the experimental group was higher than that in the control group(P = 0.044). There was no statistically difference in the incidence of treatment-related adverse events (TRAEs) between the two groups (P>0.05). The median PFS and median OS in the experimental group showed no statistically difference compared to the control group (P = 0.647; P = 0.370).ConclusionThe combination of deep hyperthermia, tislelizumab, and chemotherapy as an initial therapy for advanced squamous non-small-cell lung cancer (NSCLC) is safe and effective and should be tested on a larger scale in the future.